{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:49:08Z","timestamp":1790675348263,"version":"4.1.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.573157","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T12:37:45Z","timestamp":1601469465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines"],"prefix":"10.3389","volume":"11","author":[{"given":"Chun-Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narc\u00eds","family":"Saubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Joseph-Munn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"B1","year":"2019","journal-title":"Global HIV & AIDS statistics \u2014 2018 fact sheet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","article-title":"Antiretroviral therapy and management of HIV infection","volume":"376","author":"Volberding","year":"2010","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.antiviral.2009.09.015","article-title":"Clinical management of HIV-1 resistance","volume":"85","author":"Paredes","year":"2010","journal-title":"Antiviral Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s00018-019-03156-8","article-title":"Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs","volume":"76","author":"Sadowski","year":"2019","journal-title":"Cell Mol Life Sci."},{"key":"B5","unstructured":"Adverse effects of antiretroviral therapy for HIV infection22938\n            MontessoriV\n            PressN\n            HarrisM\n            AkagiL\n            MontanerJSG\n          14734438CMAJ.1702004"},{"key":"B6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40264-017-0505-6","article-title":"Pre-exposure prophylaxis for HIV prevention: safety concerns","volume":"40","author":"Tetteh","year":"2017","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/330687c0","article-title":"Troublesome trials for AIDS vaccines","volume":"330","author":"Ezzell","year":"1987","journal-title":"Nature."},{"key":"B8","unstructured":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","article-title":"Self-assembling protein nanoparticles in the design of vaccines","volume":"14","author":"L\u00f3pez-Sagaseta","year":"2016","journal-title":"Comput Struct Biotechnol J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines."},{"key":"B14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol Bioeng."},{"key":"B16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1586\/erv.11.37","article-title":"Virus-like particles: innate immune stimulators","volume":"10","author":"Raghunandan","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coi.2009.12.003","article-title":"Recognition of viruses by cytoplasmic sensors","volume":"22","author":"Wilkins","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-065X.1987.tb00521.x","article-title":"Antigen presentation pathways to class i and class II MHC-restricted T lymphocytes","volume":"98","author":"Braciale","year":"1987","journal-title":"Immunol Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/eji.1830261109","article-title":"Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes","volume":"26","author":"Bachmann","year":"1996","journal-title":"Eur J Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000150482","article-title":"Virus-like particles induce MHC class I-restricted T-cell responses. lessons learned from the hepatitis B small surface antigen","volume":"39","author":"Schirmbeck","year":"1996","journal-title":"Intervirology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.coviro.2013.05.004","article-title":"Virus-induced humoral immunity: on how B cell responses are initiated","volume":"3","author":"Zabel","year":"2013","journal-title":"Curr Opin Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-540-73900-5_1","article-title":"Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors","volume":"319","author":"Hinton","year":"2008","journal-title":"Curr Top Microbiol Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing antiviral B cell responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.molimm.2009.03.008","article-title":"Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells","volume":"46","author":"Zhang","year":"2009","journal-title":"Mol Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cmi.2012.61","article-title":"TLR signaling in B-cell development and activation","volume":"10","author":"Hua","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.22038\/IJBMS.2013.1345","article-title":"Human papillomavirus type16- l1 vlp production in insect cells","volume":"16","author":"Abdoli","year":"2013","journal-title":"Iran J Basic Med Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.virusres.2016.04.017","article-title":"Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic","volume":"220","author":"Chen","year":"2016","journal-title":"Virus Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/bit.21716","article-title":"Escherichia coli-based cell-free synthesis of virus-like particles","volume":"100","author":"Bundy","year":"2008","journal-title":"Biotechnol Bioeng."},{"key":"B30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bej.2009.02.006","article-title":"Challenges for the production of virus-like particles in insect cells: The case of rotavirus-like particles","volume":"45","author":"Palomares","year":"2009","journal-title":"Biochem Eng J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"6929","DOI":"10.1128\/JVI.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.biotechadv.2011.08.022","article-title":"Mammalian cell protein expression for biopharmaceutical production","volume":"30","author":"Zhu","year":"2012","journal-title":"Biotechnol Adv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"40841","DOI":"10.1074\/jbc.R112.406272","article-title":"HIV entry and envelope glycoprotein-mediated fusion","volume":"287","author":"Blumenthal","year":"2012","journal-title":"J Biol Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/v2051146","article-title":"The role of lipids in retrovirus replication","volume":"2","author":"Waheed","year":"2010","journal-title":"Viruses."},{"key":"B35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"State K laboratory of, Virology WI of, Sciences CA of, Wuhan, 430071, China. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J Immunol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.vaccine.2012.10.067","article-title":"Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(\u00ae)","volume":"31","author":"Kemp","year":"2012","journal-title":"Vaccine."},{"key":"B38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0092-8674(89)90873-8","article-title":"Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells","volume":"59","author":"Gheysen","year":"1989","journal-title":"Cell."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1128\/JVI.79.3.1701-1712.2005","article-title":"Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 gag-derived vaccines in mice","volume":"79","author":"Wong","year":"2005","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/bit.21518","article-title":"Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation","volume":"98","author":"Peacey","year":"2007","journal-title":"Biotechnol Bioeng."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1016\/j.vaccine.2013.09.003","article-title":"Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies","volume":"31","author":"Zhai","year":"2013","journal-title":"Vaccine."},{"key":"B42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1586\/erv.12.150","article-title":"Hepatitis B core-based virus-like particles to present heterologous epitopes","volume":"12","author":"Roose","year":"2013","journal-title":"Expert Rev Vaccines."},{"key":"B43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/viro.2001.1240","article-title":"Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes","volume":"293","author":"Niikura","year":"2002","journal-title":"Virology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/COH.0b013e32832edc19","article-title":"Immunogenicity of HIV-1 envelope glycoprotein oligomers","volume":"4","author":"Forsell","year":"2009","journal-title":"Curr Opin HIV AIDS"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1016\/j.vaccine.2011.05.005","article-title":"Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins","volume":"29","author":"Visciano","year":"2011","journal-title":"Vaccine."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1128\/JVI.66.7.4003-4012.1992","article-title":"Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine","volume":"66","author":"Rovinski","year":"1992","journal-title":"J Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/infdis\/174.4.862","article-title":"Immunization with recombinant p17\/p24:ty virus-like particles in human immunodeficiency virus-infected persons","volume":"174","author":"Veenstra","year":"1996","journal-title":"J Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0163-4453(97)92814-0","article-title":"A pilot phase II study of the safety and immunogenicity of HIV p17\/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects","volume":"35","author":"Peters","year":"1997","journal-title":"J Infect"},{"key":"B49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00002030-199802000-00007","article-title":"Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects","volume":"12","author":"Kelleher","year":"1998","journal-title":"AIDS"},{"key":"B50","doi-asserted-by":"publisher","first-page":"a028902","DOI":"10.1101\/cshperspect.a028902","article-title":"What is the predictive value of animal models for vaccine efficacy in humans? The importance of bridging studies and species-independent correlates of protection","volume":"10","author":"Golding","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1016\/j.vaccine.2011.07.046","article-title":"Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development","volume":"29","author":"Yuan","year":"2011","journal-title":"Vaccine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.virusres.2008.01.012","article-title":"Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles","volume":"133","author":"Halsey","year":"2008","journal-title":"Virus Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/088922200309368","article-title":"Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques","volume":"16","author":"Paliard","year":"2000","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/aid.2006.22.99","article-title":"Elicitation of immunity to HIV type 1 Gag is determined by Gag structure","volume":"22","author":"Young","year":"2006","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0166-3542(00)00136-4","article-title":"High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A","volume":"49","author":"Buonaguro","year":"2001","journal-title":"Antiviral Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1016\/j.vaccine.2011.05.004","article-title":"HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line","volume":"29","author":"Tagliamonte","year":"2011","journal-title":"Vaccine."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1128\/JVI.67.6.3191-3198.1993","article-title":"Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion","volume":"67","author":"Griffiths","year":"1993","journal-title":"J Virol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1006\/viro.1996.0293","article-title":"Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles","volume":"220","author":"Wagner","year":"1996","journal-title":"Virology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1016\/j.vaccine.2006.09.071","article-title":"Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state","volume":"25","author":"Kim","year":"2007","journal-title":"Vaccine."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2012.05.005","article-title":"Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41","volume":"431","author":"Pastori","year":"2012","journal-title":"Virology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/nsmb.2922","article-title":"Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies","volume":"21","author":"Bird","year":"2014","journal-title":"Nat Struct Mol Biol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1006\/viro.2000.0435","article-title":"Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes","volume":"273","author":"Liu","year":"2000","journal-title":"Virology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1128\/JVI.03187-14","article-title":"Structure and dynamics of the native HIV-1 Env trimer","volume":"89","author":"Munro","year":"2015","journal-title":"J Virol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1089\/aid.1995.11.1187","article-title":"Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins","volume":"11","author":"Rovinski","year":"1995","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0166-3542(02)00004-9","article-title":"Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb\/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A","volume":"54","author":"Buonaguro","year":"2002","journal-title":"Antiviral Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"14804","DOI":"10.1128\/JVI.79.23.14804-14814.2005","article-title":"Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization","volume":"79","author":"Hammonds","year":"2005","journal-title":"J Virol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0042-6822(91)90978-K","article-title":"HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles","volume":"183","author":"Haffar","year":"1991","journal-title":"Virology."},{"key":"B68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1006\/viro.1997.8668","article-title":"Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies","volume":"235","author":"Deml","year":"1997","journal-title":"Virology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.virol.2007.04.033","article-title":"A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120","volume":"366","author":"Crooks","year":"2007","journal-title":"Virology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"9586","DOI":"10.1128\/JVI.00141-06","article-title":"Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity","volume":"80","author":"Sagar","year":"2006","journal-title":"J Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1128\/JVI.00268-11","article-title":"Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies","volume":"85","author":"van Gils","year":"2011","journal-title":"J Virol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.immuni.2016.03.006","article-title":"Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected chinese donor","volume":"44","author":"Kong","year":"2016","journal-title":"Immunity."},{"key":"B73","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"McGuire","year":"2013","journal-title":"J Exp Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e1004932","DOI":"10.1371\/journal.ppat.1004932","article-title":"Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site","volume":"11","author":"Crooks","year":"2015","journal-title":"PLoS Pathog."},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1128\/JVI.00415-17","article-title":"Dense array of spikes on HIV-1 virion particles","volume":"91","author":"Stano","year":"2017","journal-title":"J Virol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1000908","article-title":"Few and far between: how HIV may be evading antibody avidity","volume":"6","author":"Klein","year":"2010","journal-title":"PLoS Pathog."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1004254","DOI":"10.1371\/journal.ppat.1004254","article-title":"Why HIV virions have low numbers of envelope spikes: implications for vaccine development","volume":"10","author":"Schiller","year":"2014","journal-title":"PLoS Pathog."},{"key":"B78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1006\/viro.1997.8669","article-title":"Increased incorporation of chimeric human immunodeficiency virus type 1gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220\/350-derived transmembrane domain","volume":"235","author":"Deml","year":"1997","journal-title":"Virology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1128\/JVI.00542-07","article-title":"Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles","volume":"81","author":"Wang","year":"2007","journal-title":"J Virol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1016\/j.vaccine.2007.01.107","article-title":"Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins","volume":"25","author":"Quan","year":"2007","journal-title":"Vaccine."},{"key":"B81","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature07469","article-title":"Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys","volume":"457","author":"Liu","year":"2009","journal-title":"Nature."},{"key":"B83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1742-4690-10-117","article-title":"GagPol-specific CD4+ T-cells increase the antibody response to Env by intrastructural help","volume":"10","author":"Nabi","year":"2013","journal-title":"Retrovirology."},{"key":"B84","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/COH.0000000000000358","article-title":"Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines","volume":"12","author":"Temchura","year":"2017","journal-title":"Curr Opin HIV AIDS."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.573157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T12:37:49Z","timestamp":1601469469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.573157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2020.573157"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.573157","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"article-number":"573157"}}